Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Public ClinicalTrials.gov record NCT06117774. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid tumors v1.1 (RECIST 1.1) and on prolonging overall survival (OS).
Study identification
- NCT ID
- NCT06117774
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 404 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 19, 2024
- Primary completion
- Apr 19, 2030
- Completion
- Apr 19, 2030
- Last update posted
- Apr 28, 2026
2024 – 2030
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | — |
| University of California Los Angeles | Santa Monica | California | 90404 | — |
| Yale New Haven Hospital | New Haven | Connecticut | 06510 | — |
| Boca Raton Clinical Research Global South Florida | Plantation | Florida | 33322 | — |
| University of Louisville James Graham Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Our Lady of the Lake Cancer Institute | Baton Rouge | Louisiana | 70808 | — |
| Morristown Medical Center | Morristown | New Jersey | 07960 | — |
| New York University Grossman School of Medicine and New York University Langone Hospitals | New York | New York | 10016 | — |
| Perlmutter Cancer Center at New York University Langone Hospital - Long Island | New York | New York | 10016 | — |
| Montefiore Einstein Center for Cancer Care | The Bronx | New York | 10461 | — |
| FirstHealth Cancer Center | Pinehurst | North Carolina | 28374 | — |
| Lehigh Valley Health Network | Allentown | Pennsylvania | 18103 | — |
| Spokenword Clinical Trials | Easton | Pennsylvania | 18045 | — |
| Renovatio Clinical | The Woodlands | Texas | 77380 | — |
| US Oncology Research Investigational Products Center | The Woodlands | Texas | 77380 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| West Virginia University Health Sciences Center | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 186 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06117774, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06117774 live on ClinicalTrials.gov.